Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial.
J. Baselga
Consultant or Advisory Role - Novartis
M. Campone
No relevant relationships to disclose
M. J. Piccart-Gebhart
No relevant relationships to disclose
H. A. Burris
No relevant relationships to disclose
H. S. Rugo
Research Funding - Novartis; Pfizer
S. Noguchi
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
M. Gnant
Consultant or Advisory Role - Amgen; AstraZeneca; Novartis; Roche; Sanofi
Honoraria - AstraZeneca; Novartis; Sanofi
Research Funding - Amgen; AstraZeneca; Pfizer; Roche; Sanofi
K. I. Pritchard
Consultant or Advisory Role - Abraxis BioScience; Boehringer Ingelheim; Novartis; Pfizer; Roche
Honoraria - Abraxis BioScience; Boehringer Ingelheim; Novartis; Pfizer; Roche
F. Lebrun
No relevant relationships to disclose
J. T. Beck
Research Funding - Novartis; Pfizer
Y. Ito
No relevant relationships to disclose
D. A. Yardley
Consultant or Advisory Role - Novartis (U)
I. Deleu
No relevant relationships to disclose
A. Perez
No relevant relationships to disclose
T. D. Bachelot
Consultant or Advisory Role - Novartis
Research Funding - Novartis
L. Vittori
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
P. Mukhopadhyay
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
D. Weber
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
T. Sahmoud
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
G. N. Hortobagyi
Consultant or Advisory Role - Allergan; Genentech; Merck; Novartis; Sanofi ; Taivex Therapeutics
Research Funding - Novartis